cyrilzakka/clinical-trials huggingface dataset:
The Effect of Proximity on Flu-Shot Participation

Using desk location information and employees' building entry/exit swipe card data from a company that offered a free 2-day worksite influenza vaccination clinic, we separately identify the vaccination effects of base proximity-the inverse of walking distance between one's desk and the clinic-and functional proximity-the likelihood of passing near the clinic during the course of a normal work day (ie, days when the clinic is not open).

We study the 2011 influenza vaccine uptake of employees at the headquarters of a health benefits administrator in the United States. These employees are generally not health care personnel. All of them have health insurance. Of the company's total workforce (including those not based at the headquarters), 26% are African Americans and 37% are racial minorities.

There are 2 main buildings at the company headquarters. Building One houses 520 employees and is the site of the vaccination clinic; Building Two houses 1281 employees. The 2 buildings are 131 meters apart and connected by an enclosed passageway. The clinic was located near the cafeteria in Building One and adjacent to the passageway connecting the 2 buildings. The clinic was conducted from October 19 to 20, 2011, and it was advertised during the 3 weeks prior.

The company requires employees to swipe a personalized electronic badge to open the external doors of its buildings, which include the doors to the passageway between the buildings. The company provided us data on the date and time of each swipe in September and October 2011. If an employee swipes her badge and holds the door open for another employee, we do not observe that other employee. The badge swipe data are therefore an incomplete measure of all movements between the buildings. The company also gave us data on employee characteristics and vaccination uptake, scaled architectural plans of the buildings, and employee desk maps.

Eligibility Criteria:
Inclusion Criteria:

* Employee of Express Scripts.
* Eligible to receive a flu shot at Express Scripts.
* Over 18 years of age.

Exclusion Criteria:

* Children
* Non Express Scripts employees
A Study of HS-20110 in Participants with Advanced Solid Tumors

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors


Eligibility Criteria:
Inclusion Criteria:

1. Males or females, aged ≥ 18 years.
2. Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
3. Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1.

Exclusion Criteria:

1. Participants have received or are receiving the following treatment:

   1. Drug therapy targeting CDH17 (such as small molecule targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor T cells).
   2. Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.
   3. Local radiotherapy within 2 weeks prior to the first dose of study treatment; irradiation of more than 30% of bone marrow or extensive radiotherapy within 4 weeks prior to the first dose of study treatment.
   4. Major surgery within 4 weeks prior to the first dose of study treatment.
   5. Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.
   6. Current use of drugs known to prolong the QT interval or that may cause torsade de pointes. Participants who need to receive these drugs during the study period should also be excluded.
   7. Live vaccine or live-attenuated vaccine within 28 weeks prior to the first dose.
2. Participants who have any Grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior therapies (except alopecia and residual neurotoxicity).
3. Inadequate bone marrow reserve or hepatic and renal functions.
4. Participants with a history of severe allergy (such as anaphylactic shock), previous severe infusion reactions, or allergy to recombinant human or murine proteins.
5. Participants who are allergic to any component of HS-20110.
Use of Whole Body Vibration in Patients With Fibromyalgia

The objective of this study is to evaluate the efficacy of a 3-month program consisted of the use of whole body vibration (WBV) in patients with fibromyalgia in order to determine whether this intervention would be effective to short and medium-term improvement of symptoms in these patients.

This was a single blind randomized controlled trial. Forty patients of FM group were assigned randomly to 2 study groups: 20 patients will be part of the experimental group (EG) that will perform a neuromuscular treatment using the vertical whole body vibration platform and another 20 will constitute the control group (CG). All these subjects will sign the corresponding informed consent for their participation in the study, according to the ethical criteria established in the Helsinki Declaration. The study took place between January and Juny 2019. Two groups of variables were analyzed in the present study three times: before, after and follow-up after three months of the intervention.

Eligibility Criteria:
Inclusion Criteria:

* Patients with FM were included in the study if they fulfilled the 1990 classification criteria of the American College of Rheumatology for fibromyalgia.
* Pain-free volunteers were included if they did not present pain symptoms or some type of treatment in any part of the body during the previous 12 months.

Exclusion Criteria:

* Participants were excluded from the study if they had not signed the informed consent or if they reported any other musculoskeletal disorder rather than patients with FM, any neurological disorder or had previous spinal fusion surgery or spinal cord stimulation.
COMPARATIVE STUDY BETWEEN TERNAMIAN BLADELESS TROCAR ENTRY and VISUAL TRANSPARENT BLADED TROCAR ENTRY in LAPAROSCOPIC PROCEDURES

To compare the efficacy and safety between Ternamian bladeless trocar entry and visual, transparent bladed trocar entry in laparoscopic procedures. A prospective randomized controlled study will be conducted among 100 female patients who will be admitted to the department of Gynecology and Obstetrics at Kasr Alainy university hospital for diagnostic and/or therapeutic laparoscopic intervention. Patients will be randomly assigned (1:1) using computer-generated random numbers to undergo laproscopic entry either by the visual transparent bladed trocar or the Ternamian bladeless trocar.

Main outcome measures: entry time of trocar entry in seconds and visceral or major vascular injury during trocar entry.

To compare the efficacy and safety between Ternamian bladeless trocar entry and visual transparent bladed trocar entry in laparoscopic procedures. A prospective randomized controlled study will be conducted among 100 female patients who were admitted to the department of Gynecology and Obstetrics at Kasr Alainy university hospital for diagnostic and/or therapeutic laparoscopic intervention. Patients were randomly assigned (1:1) using computer-generated random numbers to undergo laproscopic entry either by the visual transparent bladed trocar or the Ternamian bladeless trocar. Entry time in seconds starting from the moment the trocar is applied through the umbilical incision to the moment the peritoneal cavity is entered, guided by transmitted images on the monitor, will be used to assess the efficacy of the used trocar type. Complications including major vessel injury or visceral injury that maybe encountered during laparoscopic entry could be immediately detected in both groups through the transmitted in time monitor images to assess safety of the used trocar type.

Main outcome measures: entry time of trocar entry in seconds and visceral or major vascular injury during trocar entry.

Eligibility Criteria:
Inclusion Criteria:

* included patients aged from 20 to 50 years old with uterine and/or adnexal benign lesions, infertility, or chronic pelvic pain indicated for diagnostic and/or therapeutic intervention, and with a body mass index (BMI) less than 40.

Exclusion Criteria:

* included patients who have had a history suggestive of pelvic adhesions as previous 4 or more laparotomies, a history of bleeding tendency, and patients with suspected pelvic malignancies.
Micra Transcatheter Pacing System Continued Access Study Protocol

Medtronic is sponsoring the Micra Continued Access (CA) study to provide continued access to the Micra System while the marketing application is under review by the Food and Drug Administration (FDA).

The Micra CA study is a prospective, non-randomized, multi-center, study designed to allow controlled access of the Micra system when used as intended. All subjects enrolled in the Micra CA Study will be prospectively followed from implant, at 6-month intervals until study closure (i.e. FDA approval). Patients with previous or existing inactive implanted cardiac stimulation systems will have additional follow ups.

Eligibility Criteria:
Inclusion Criteria:

* Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
* Subject meets Class I or ll indication for implantation of single chamber ventricular pacemaker and is intended to be implanted with a Micra System
* Subject able and accessible for follow-up per study requirements
* Subject is at least 18 years of age
* Patient is not enrolled in a concurrent drug and/or device study that may confound registry result.

Exclusion Criteria:

* Subject has had an acute myocardial infraction (AMI) within 30 days of implant
* Subject has implantation of neurostimulator or any other chronically implanted device which uses current in the body
* Subject with mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD)
* Subjects who are morbidly obese and physician believes telemetry communication of ≤5 inches (12.5 cm) could not be obtained with programmer head.
* Subject who femoral venous anatomy is unable to accommodate a 23 French introducer sheath or implant on the right side of the heart (for example due to obstructions or sever tortuosity) in the opinion of the implanter
* Subjects with known intolerance to Nickel-Titanium (Nitinol) Alloy
* Subject for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated
* Subjects with life expectancy less than 12-months
* Subject is enrolled in a concurrent drug and/or device study that may confound CA study results
Omega-3 Supplementation After Surgical Treatment of Obesity

The study evaluates diet supplementation of Omega-3 fatty acids after surgical treatment of obesity in adults. Half participants will receive diet supplementation of Omega-3 fatty acids, while the other half will receive placebo.

Omega-3 fatty acids has been related to immunomodulation and antioxidant action. Diet supplementation of Omega-3 fatty acids after surgical treatment of obesity may help stabilize protein catabolism, reduce peroxidative damage, and improve lipid profile.

Eligibility Criteria:
Inclusion Criteria:

* BMI \> 30kg/m2
* Candidate to bariatric and metabolic surgery

Exclusion Criteria:

* Use of Omega-3
* Contraindication to bioimpedance analysis
* Uso of steroids, non steroidal inflammatory drugs, immunomodulators or antibiotics
* Refusal to participate
Comparative Evaluation of an Alkasite-based Restorative Material and Two Different Resin Composites

The clinical performance of an an alkasite-based restorative material and two different resin composites will be evaluated and compared in non-carious cervical lesions. After recruiting participants with at least three non-carious cervical lesions, all restorations will be placed by a single clinician. Lesions will be divided in three groups: an alkasite-based restorative material (Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN)), hybrid resin composite (Gradia Direct Anterior, GC, Tokyo, Japan (GD)) and a highly filled flowable resin composite ((G-aenial Universal Flo, GC, Tokyo, Japan (GF)). All restorative procedures will be conducted according to manufacturers' instructions. Restorations will be scored using FDI criteria. Descriptive statistics will be performed using chi-square tests.


Eligibility Criteria:
Inclusion Criteria:

* Age range will be 18 to 65.
* They will be required to have at least three NCCLs needed restoration in different teeth.
* All the NCCLs selected will be in similar sizes.

Exclusion Criteria:

* Patients with severe periodontal disease
* Patients with rampant, uncontrolled caries
* Patients with xerostomia
* Patients with serious medical problems preventing them from attending review visits
* Patients with poor gingival health
* Patients with heavy bruxism
* Patients with removable partial dentures
* Patients undergoing bleaching treatment or orthodontic treatment
Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain information on factors potentially influencing the patients' level of activity.


Eligibility Criteria:
Inclusion Criteria:

* Multiple sclerosis diagnosed within the last 12 months
* Clinically isolated Syndrome (CIS), under Interferon-beta-1b treatment
I-scan for Adenoma Detection

This study is a randomized controlled trial to determine whether i-scan can improve the detection of conventional adenomas and sessile serrated adenomas/polyps.

This is a randomized controlled trial comparing the use of i-scan (digital surface and contrast enhancement of the mucosa) versus standard high-definition white light for the detection of conventional adenomas and sessile serrated adenomas/polyps. Recent studies have indicated that colonoscopy is more effective in preventing cancer in the left side of the colon than the right side of the colon. The reasons for this difference may be partly biologic, in that a special group of polyps known as sessile serrated adenomas/polyps (SSA) are located primarily proximal to the splenic flexure. Sessile serrated adenomas/polyps share molecular features with a group of cancers that occur primarily in the proximal colon. These molecular features include CpG island methylator phenotype (CIMP) and microsatellite instability. These lesions are endoscopically subtle in that they are often flat, have the same color as the surrounding mucosa, and are hard to differentiate from normal mucosa. Recent studies have shown that image enhanced endoscopy can highlight the appearance of these lesions. This study will test whether i-scan increases the detection of conventional adenomas and sessile serrated adenomas/polyps in a randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* Age 50-75
* Intact colon and rectum
* Willing to sign an informed consent form

Exclusion Criteria:

* Subjects less than 50 years of age or greater than 75 years of age
* Subjects who are in the inpatient unit
* Subjects with diverticulitis,
* Subjects with inflammatory bowel disease
* Subjects with polyposis syndromes
* Subjects with previous surgical resection of any portion of the colon or rectum
* Subjects referred for endoscopic resection of previously diagnosed colorectal polyp
Eradication of H. Pylori Infection With Moxifloxacin

The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.

Patients who were confirmed to be positive for Helicobacter Pylori infection were randomly assigned to the eradication treatments. At four weeks after completion of eradication therapy, H. pylori tests were performed with a Stool antigen test.

Eligibility Criteria:
Inclusion Criteria:

1. Successful isolation of H. pylori from the patient, and
2. patients of at least 18 years of age.

Exclusion Criteria:

1. age under 18 years
2. presence of clinically signiﬁcant associated conditions (insulin-dependent diabetes mellitus, gastrointestinal bleeding, neoplastic diseases, coagulation disorders, and neurologic, metabolic, hematological or endocrine hepatic, cardiorespiratory, or renal diseases),
3. previous gastric surgery,
4. allergy to any of the drugs used in the study, and (5) pregnancy or breastfeeding.
Effects of Sustained Natural Apophyseal Glides Versus Cervical Manipulation on Pain and Disability in Wrestle

This study will be conducted to evaluate effect of sustained natural apophyseal glides and cervical manipulation in pain and disability of neck among wrestler players .All subjects will be selected between ages 18 to 35 years. Data will be collected from players in registered gujranwala wrestling clubs. Study design will be Randomized Clinical Trial. Neck pain disability index questionnaire and NPRS will be used to check the disability in neck and intensity of pain respectively. Informed consent will be taken from all participants. Study will be conducted in 6 weeks' time period. Data will be collected at the start of research and after six week post research date will collected for analysis. Patients will be allocated randomly into two main groups. Group A is the interventional group and group B is the control group. On group A snag will be performed and Group B will be provided by cervical manipulation to compare the effects of both techniques. SPSS will be used for data entry and analysis.

The main aim of the study is to compare the effects of sustained natural apophyseal glides versus cervical manipulation on pain and disability in Nonspecific acute neck pain among wrestlers. Acute neck pain and disabilities are most common among wrestlers. Different studies occur on snags and mobilizations on various athletes but there is a literature gap between comparison of Snags and cervical manipulation in neck disabilities.

This study will be conducted to evaluate effect of sustained natural apophyseal glides and cervical manipulation in pain and disability of neck among wrestler players .All subjects will be selected between ages 18 to 35 years. Data will be collected from players in registered gujranwala wrestling clubs. Study design will be Randomized Clinical Trial. Neck pain disability index questionnaire and NPRS will be used to check the disability in neck and intensity of pain respectively. Informed consent will be taken from all participants. Study will be conducted in 6 weeks' time period. Data will be collected at the start of research and after six week post research date will collected for analysis. Patients will be allocated randomly into two main groups. Group A is the interventional group and group B is the control group. On group A snag will be performed and Group B will be provided by cervical manipulation to compare the effects of both techniques. SPSS will be used for data entry and analysis.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 35 years male only
* Acute non-specific neck pain

Exclusion Criteria:

* Patients with history of discogenic cause in neck.
* History of Postoperative patients
* Individuals who was not willing and individuals with systemic disorders
* Any musculoskeletal(MSK) injury that effect their performance like fracture and bruises etc.
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.


Eligibility Criteria:
Inclusion Criteria

-Medical records of patients initiating treatment for Ph- R/R ALL at participating clinical centers in the US between January 2013 and March 2019 will be eligible for inclusion.

Exclusion Criteria

* Medical records of patients with Ph+ ALL will be excluded.
* If informed consent is required, medical records of patients who do not provide informed consent will be excluded.
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit

This study will test the effectiveness of mailed, smartphone urinalysis kits to improve albuminuria screening compliance and detection of albuminuria.

This proposal will examine the effect of mailed, smartphone urinalysis kits to improve albuminuria screening compliance and detection of albuminuria. The investigators will randomize 1,000 non-diabetic MyGeisinger portal users with hypertension and last clinic blood pressure \>= 130/80 mmHg who have not received albuminuria screening to either: 1) control - usual care or 2) intervention - mailed urinalysis smartphone kit. All patients will first receive a reminder letter to have albuminuria screening completed at their clinic in coordination with the Geisinger Care Gap Team. Patients randomized to the intervention arm who do not complete this initial screening test will then be offered a mailed, smartphone urinalysis testing kit. Patients with 1+ or greater detected urine protein will be recommended to have urine albumin/creatinine ratio (ACR) testing to confirm albuminuria. Patients with ACR \>= 30 mg/g will be referred to pharmacists for optimal treatment of albuminuria (ACE or ARB, statin, BP goal \<130/90 mmHg).

Eligibility Criteria:
Inclusion Criteria:

* 18 and older
* Hypertension
* Last outpatient BP ≥ 130/80 mmHg
* Active MyGeisinger users with a listed mobile phone number
* Has a Geisinger PCP and followed by the Care Gaps team
* No prior urine albuminuria test (urine dipstick, albumin/creatinine ratio, protein/creatinine ratio)

Exclusion Criteria:

* History of diabetes
* Receiving dialysis
* History of kidney transplant
* eGFR \< 15 ml/min/1.73m2
* Principal investigator or PCP discretion (i.e. concerns about safety, compliance)
Maturity and Motor Fitness

The current study examined the effect of maturity on the sprint and jump performances in a single year age group of 13 year old boys.

The investigators examined the issue in adolescent boys (n = 107) aged from 13.0 to 13.9 years. The maturity status was assessed using a self-assessment of stage of pubic hair based on the criteria of Tanner. Body composition and maximal voluntary knee extension torque (KET) were determined using a bioelectrical impedance analyzer and a static myometer, respectively. Sprint velocity was measured by a non-motorized treadmill. Jump height was calculated from the following equation; g × (flight time)2 × 8 × 10-1. The flight time during jumping was measured by a matswitch system.

Eligibility Criteria:
Inclusion Criteria:

* adolescents

Exclusion Criteria:

* subjects had some diseases and disorders